Evidence map›Paper›PMID 38062776›Full record

ArticleHuman gene therapy2024

A Novel Role for the Adenovirus L4 Region 22K and 33K Proteins in Adeno-Associated Virus Production.

Angela Adsero, Brendan Chestnut, Sara Shahnejat-Bushehri, Lalita Sasnoor, Travis McMurphy, Mike Swenor, Ryan Pasquino, Arun Pradhan, Victor Hernandez, Linas Padegimas and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Human gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Angela AdseroMolecular Development, Forge Biologics, Grove City, Ohio, USA.ORCID 0009-0006-4687-7053
Brendan ChestnutMolecular Development, Forge Biologics, Grove City, Ohio, USA.
Sara Shahnejat-BushehriMolecular Development, Forge Biologics, Grove City, Ohio, USA.
Lalita SasnoorMolecular Development, Forge Biologics, Grove City, Ohio, USA.
Travis McMurphyMolecular Development, Forge Biologics, Grove City, Ohio, USA.
Mike SwenorMolecular Development, Forge Biologics, Grove City, Ohio, USA.
Ryan PasquinoMolecular Development, Forge Biologics, Grove City, Ohio, USA.
Arun PradhanMolecular Development, Forge Biologics, Grove City, Ohio, USA.
Victor HernandezMolecular Development, Forge Biologics, Grove City, Ohio, USA.
Linas PadegimasMolecular Development, Forge Biologics, Grove City, Ohio, USA.
David DismukeChief Technical Officer, Forge Biologics, Grove City, Ohio, USA.
Grove City College · USCenter for Biologics Evaluation and Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite decades of research in adeno-associated virus (AAV) and the role of adenovirus in production, the interplay of AAV and adenovirus is not fully understood. Specific regions of the adenoviral genome containing E1, E2a, E4 open reading frame (ORF), and VA RNA have been demonstrated as necessary for AAV production; however, incorporating these regions into either a producer cell line or subcloning into an Ad helper plasmid may lead to inclusion of neighboring adenoviral sequence or ORFs with unknown function. Because AAV is frequently used in gene therapies, removing excessive adenovirus sequences improves the Ad helper plasmid size and manufacturability, and may lead to safer vectors for patients. Furthermore, deepening our understanding of the helper virus genes required for recombinant AAV (rAAV) production has the potential to increase yields and manufacturability of rAAV for clinical and commercial applications. One region continuously included in various Ad helper plasmid iterations is the adenoviral E2a promoter region that appears to be necessary for E2a expression. Due to the compact nature of viral genomes, the E2a promoter region overlaps with the Hexon Assembly/100K protein and the L4 region. The L4 region, which contains the coding sequences for 22K and 33K proteins, had not been thought to be necessary for AAV production. Through molecular techniques, this study demonstrates that the adenoviral 22K protein is essential for rAAV production in HEK293 cells by triple transfection and that the 33K protein synergistically increases rAAV yield.

Indexed as

AdenoviridaeDependovirusGenetic VectorsHEK293 CellsHumansPlasmidsTransfectionViral ProteinsViral ProteinsAAVadeno-associated virusadenovirusE2aL4 22KL4 33K

Identifiers

PMID38062776
PMCPMC10818037
OpenAlexW4389486126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.